PRTA - Prothena Corp PLC Stock Price, Fair Value and News

23.14USD-0.40 (-1.70%)Market Closed

Market Summary

USD23.14-0.40

Market Closed

-1.70%

PRTA Stock Price

View Fullscreen

PRTA RSI Chart

PRTA Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-7.22

Price/Sales (Trailing)

13.62

EV/EBITDA

-4.55

Price/Free Cashflow

-7.8

PRTA Price/Sales (Trailing)

PRTA Profitability

EBT Margin

-202.63%

Return on Equity

-34.32%

Return on Assets

-27.66%

Free Cashflow Yield

-12.82%

PRTA Fundamentals

PRTA Revenue

Revenue (TTM)

91.4M

Rev. Growth (Yr)

-99.37%

Rev. Growth (Qtr)

-99.63%

PRTA Earnings

Earnings (TTM)

-172.4M

Earnings Growth (Yr)

-54.15%

Earnings Growth (Qtr)

-7.06%

Breaking Down PRTA Revenue

Last 7 days

8.0%

Last 30 days

-2.3%

Last 90 days

-15.6%

Trailing 12 Months

-69.5%

How does PRTA drawdown profile look like?

PRTA Financial Health

Current Ratio

13.08

PRTA Investor Care

Shares Dilution (1Y)

1.93%

Diluted EPS (TTM)

-3.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	54.9M	57.6M	141.0M	91.4M
2022	163.9M	127.2M	90.6M	53.9M
2021	50.8M	100.7M	150.6M	200.6M
2020	769.0K	797.0K	749.0K	853.0K
2019	914.0K	802.0K	752.0K	814.0K
2018	20.9M	14.2M	7.6M	955.0K
2017	7.7M	14.3M	20.9M	27.5M
2016	1.3M	1.3M	1.2M	1.1M
2015	38.5M	26.2M	13.9M	1.6M
2014	21.0M	30.9M	40.9M	50.9M
2013	2.4M	1.9M	1.1M	11.0M
2012	1.0M	1.6M	2.1M	2.7M
2011	0	0	0	507.0K
2010	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Prothena Corp PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 24, 2024	walker karin l	sold	-170,000	34.00	-5,000	chief accounting officer
Jan 24, 2024	walker karin l	acquired	67,650	13.53	5,000	chief accounting officer
Dec 20, 2023	walker karin l	sold	-185,952	37.1903	-5,000	chief accounting officer
Dec 20, 2023	walker karin l	acquired	67,650	13.53	5,000	chief accounting officer
Nov 30, 2023	walker karin l	sold	-170,000	34.00	-5,000	chief accounting officer
Nov 30, 2023	walker karin l	acquired	67,650	13.53	5,000	chief accounting officer
Oct 25, 2023	walker karin l	sold	-205,191	41.0383	-5,000	chief accounting officer
Oct 25, 2023	walker karin l	acquired	67,650	13.53	5,000	chief accounting officer
Oct 11, 2023	smith brandon s.	acquired	44,480	11.12	4,000	chief operating officer
Oct 11, 2023	smith brandon s.	sold	-186,985	46.7462	-4,000	chief operating officer

Which funds bought or sold PRTA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	new	-	342,272	342,272	0.02%
May 07, 2024	Headlands Technologies LLC	new	-	96,132	96,132	0.02%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	78.53	264,790	1,485,700	-%
May 07, 2024	OPPENHEIMER & CO INC	sold off	-100	-229,887	-	-%
May 07, 2024	Arizona State Retirement System	reduced	-1.46	-133,936	273,981	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-3.86	-422,000	801,000	-%
May 07, 2024	Susquehanna Portfolio Strategies, LLC	sold off	-100	-732,542	-	-%
May 07, 2024	Swiss National Bank	unchanged	-	-916,344	1,961,780	-%
May 07, 2024	ASSETMARK, INC	sold off	-100	-109	-	-%
May 06, 2024	Jefferies Financial Group Inc.	sold off	-100	-148,851	-	-%

Are Funds Buying or Selling PRTA?

Are funds buying PRTA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRTA

No. of Funds

Unveiling Prothena Corp PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	fennell todd w.	5.85%	3,141,459	SC 13G
Feb 14, 2024	price t rowe associates inc /md/	7.9%	4,243,010	SC 13G/A
Feb 14, 2024	scully william p	6.53%	3,502,481	SC 13G
Feb 13, 2024	avidity partners management lp	0%	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 02, 2024	blackrock inc.	7.0%	3,770,650	SC 13G/A
Jan 24, 2024	state street corp	5.14%	2,758,564	SC 13G
Mar 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	avidity partners management lp	5.7%	2,953,000	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	6.3%	3,205,903	SC 13G/A

Recent SEC filings of Prothena Corp PLC

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Mar 29, 2024	ARS	ARS
Mar 29, 2024	DEF 14A	DEF 14A
Mar 29, 2024	DEFA14A	DEFA14A
Mar 05, 2024	3	Insider Trading
Mar 05, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading

Peers (Alternatives to Prothena Corp PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Prothena Corp PLC News

Latest updates

Prothena Corp PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	316,000	84,866,000	4,019,000	2,169,000	49,923,000	1,517,000	1,312,000	1,242,000	1,172,000	139,174,000	60,071,000	30,215,500	360,000	157,000	195,000	141,000	256,000	205,000	167,000	186,000
Operating Expenses	3.5%	81,578,000	78,831,000	74,558,000	70,523,000	58,494,000	49,995,000	51,849,000	44,521,000	39,097,000	34,264,000	29,947,000	32,122,000	32,269,000	30,668,000	31,003,000	26,927,000	24,989,000	23,530,000	21,177,000	18,664,000	23,140,000
S&GA Expenses	-100.0%	-	16,940,000	16,645,000	14,512,000	13,738,000	13,124,000	11,989,000	12,952,000	11,835,000	12,206,000	11,955,000	11,032,000	11,125,000	9,908,000	9,398,000	9,656,000	9,741,000	8,059,000	8,691,000	9,081,000	9,905,000
R&D Expenses	3.6%	64,114,000	61,891,000	57,913,000	56,011,000	44,756,000	36,871,000	39,860,000	31,569,000	27,262,000	22,058,000	17,992,000	21,090,000	21,144,000	20,760,000	21,605,000	17,271,000	15,248,000	15,471,000	12,486,000	9,583,000	13,296,000
EBITDA Margin	-18.8%	-1.67	-1.41	-0.42	-2.31	-2.25	-2.20	-1.75	-0.02	0.41	0.36	0.50	-0.63	-	-	-	-	-	-	-	-	-
Interest Expenses	-11.6%	7,165,000	8,102,000	8,522,000	7,700,000	6,690,000	3,744,000	1,913,000	639,000	53,000	12,000	11,000	8,000	11,000	10,000	43,000	179,000	1,137,000	1,569,000	2,034,000	2,296,000	2,304,000
Income Taxes	30.2%	-2,200,000	-3,150,000	-3,092,000	-4,300,000	-2,912,000	-2,994,000	-2,653,000	-1,300,000	-1,671,000	60,000	-51,000	300,000	4,660,000	353,000	-215,000	-255,000	-166,000	-131,000	468,000	-156,000	198,000
Earnings Before Taxes	-5.4%	-74,440,000	-70,618,000	18,815,000	-58,901,000	-49,776,000	3,345,000	-48,417,000	-42,572,000	-37,961,000	-33,096,000	109,196,000	27,896,000	-32,075,000	-30,363,000	-30,792,000	-26,537,000	-23,735,000	-21,685,000	-18,980,000	-15,966,000	-20,667,000
EBT Margin	-15.4%	-2.03	-1.76	-0.61	-2.67	-2.50	-2.33	-1.79	-0.03	0.40	0.36	0.50	-0.65	-	-	-	-	-	-	-	-	-
Net Income	-7.1%	-72,239,000	-67,476,000	21,907,000	-54,595,000	-46,864,000	6,349,000	-45,764,000	-41,244,000	-36,290,000	-33,179,000	109,247,000	27,642,000	-36,735,000	-30,716,000	-30,577,000	-26,282,000	-23,569,000	-21,554,000	-19,448,000	-15,810,000	-20,865,000
Net Income Margin	-17.3%	-1.89	-1.61	-0.52	-2.44	-2.32	-2.17	-1.73	-0.01	0.41	0.33	0.46	-0.70	-	-	-	-	-	-	-	-	-
Free Cashflow	-43.1%	-73,051,000	-51,038,000	9,517,000	-44,927,000	-47,458,000	-4,976,000	-31,167,000	-35,263,000	-37,415,000	-22,458,000	112,110,000	36,619,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.5%	623	696	747	721	742	758	554	550	581	609	633	436	380	333	356	379	399	419	451	462	460
Current Assets	-11.5%	566	639	691	677	700	719	525	521	556	585	608	409	352	299	320	341	360	378	409	419	415
Cash Equivalents	-11.3%	549	619	671	659	686	710	496	509	543	579	600	400	343	298	315	334	353	378	390	398	410
Net PPE	-4.3%	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	5.00
Liabilities	-10.5%	121	135	130	139	134	136	150	142	143	143	142	148	145	149	146	144	144	146	162	159	147
Current Liabilities	-23.9%	43.00	57.00	53.00	72.00	49.00	50.00	51.00	40.00	36.00	33.00	29.00	53.00	23.00	26.00	22.00	19.00	17.00	18.00	32.00	28.00	15.00
Shareholder's Equity	-10.5%	502	561	617	582	607	622	405	407	439	466	490	288	235	184	210	234	255	273	289	303	312
Retained Earnings	-7.4%	-1,052	-980	-912	-934	-879	-833	-839	-793	-752	-716	-682	-792	-819	-783	-752	-721	-695	-671	-650	-630	-615
Additional Paid-In Capital	0.9%	1,554	1,541	1,529	1,516	1,487	1,455	1,244	1,200	1,191	1,182	1,173	1,080	1,054	967	961	956	950	944	939	933	927
Shares Outstanding	0.1%	54.00	54.00	54.00	53.00	53.00	52.00	47.00	47.00	47.00	44.00	46.00	44.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,900	-	-	-	956	-	-	-	1,728	-	-	-	319	-	-	-	329	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-43.1%	-73,051	-51,038	9,517	-44,927	-47,458	-4,976	-31,167	-35,263	-37,415	-22,458	112,110	36,619	-33,666	-19,094	-19,404	-18,697	-23,167	-14,488	-8,943	-12,103	-17,435
Share Based Compensation	11.8%	12,383	11,080	10,944	10,100	8,790	7,433	7,966	8,263	7,660	6,887	6,055	-	-	5,068	5,583	5,687	-	-	5,816	6,277	-
Cashflow From Investing	93.2%	-103	-1,512	-442	-771	-48.00	-151	-130	-161	-22.00	-319	-208	-	-48.00	-51.00	-77.00	-46.00	-22.00	-106	-249	-69.00	-123
Cashflow From Financing	73.1%	836	483	2,711	18,625	23,284	220,765	18,130	1,225	1,337	1,773	87,013	20,219	81,327	-	64.00	-	151	13.00	-	210	5.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PRTA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues	$ 91,370	$ 53,905	$ 200,577
Operating expenses:
Research and development	220,571	135,562	82,284
General and administrative	61,835	49,900	46,318
Total operating expenses	282,406	185,462	128,602
Income (loss) from operations	(191,036)	(131,557)	71,975
Other income (expense):
Interest income	31,014	6,349	42
Other expense, net	(458)	(397)	(96)
Total other income (expense), net	30,556	5,952	(54)
Income (loss) before income taxes	(160,480)	(125,605)	71,921
Provision for (benefit from) income taxes	(13,452)	(8,656)	4,946
Net income (loss)	$ (147,028)	$ (116,949)	$ 66,975
Earnings Per Share, Basic	$ (2.76)	$ (2.47)	$ 1.51
Earnings Per Share, Diluted	$ (2.76)	$ (2.47)	$ 1.38
Weighted Average Number of Shares Outstanding, Basic	53,216	47,369	44,228
Weighted Average Number of Shares Outstanding, Diluted	53,216	47,369	48,464
Collaboration revenue
Revenues	$ 91,320	$ 13,855	$ 139,833
Revenue from license and intellectual property
Revenues	$ 50	$ 40,050	$ 60,744

PRTA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 618,830	$ 710,406
Accounts receivable	5,159	0
Prepaid expenses and other current assets	13,941	8,692
Restricted cash, current	1,352	0
Total current assets	639,282	719,098
Non-current assets:
Property and equipment, net	3,836	1,731
Operating lease right-of-use assets	12,162	6,277
Deferred tax assets	33,893	18,204
Restricted cash, non-current	860	2,212
Other non-current assets	6,349	10,513
Total non-current assets	57,100	38,937
Total assets	696,382	758,035
Current liabilities:
Accounts payable	25,391	9,270
Accrued research and development	14,724	10,794
Deferred revenue, current	0	11,442
Lease liability, current	1,114	6,473
Other current liabilities	15,662	12,168
Total current liabilities	56,891	50,147
Non-current liabilities:
Deferred revenue, non-current	67,405	85,293
Lease liability, non-current	10,721	0
Other liabilities	0	553
Total non-current liabilities	78,126	85,846
Total liabilities	135,017	135,993
Commitments and contingencies (Note 6)
Shareholders’ equity:
Euro deferred shares, €22 nominal value: Authorized shares — 10,000 at December 31, 2023 and 2022 Issued and outstanding shares — none at December 31, 2023 and 2022	0	0
Ordinary shares, $0.01 par value: Authorized shares — 100,000,000 at December 31, 2023 and 2022 Issued and outstanding shares — 53,682,117 and 52,103,608 at December 31, 2023 and 2022, respectively	537	521
Additional paid-in capital	1,540,859	1,454,524
Accumulated deficit	(980,031)	(833,003)
Total shareholders’ equity	561,365	622,042
Total liabilities and shareholders’ equity	$ 696,382	$ 758,035

About Prothena Corp PLC

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual AÃƒÅ¸-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

CEO	Dr. Gene G. Kinney Ph.D.
WEBSITE	prothena.com
INDUSTRY	Biotechnology
EMPLOYEES	127

Prothena Corp PLC Frequently Asked Questions

What is the ticker symbol for Prothena Corp PLC? What does PRTA stand for in stocks?

PRTA is the stock ticker symbol of Prothena Corp PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Prothena Corp PLC (PRTA)?

As of Wed May 08 2024, market cap of Prothena Corp PLC is 1.24 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRTA stock?

You can check PRTA's fair value in chart for subscribers.

What is the fair value of PRTA stock?

You can check PRTA's fair value in chart for subscribers. The fair value of Prothena Corp PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Prothena Corp PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Prothena Corp PLC a good stock to buy?

The fair value guage provides a quick view whether PRTA is over valued or under valued. Whether Prothena Corp PLC is cheap or expensive depends on the assumptions which impact Prothena Corp PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRTA.

What is Prothena Corp PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, PRTA's PE ratio (Price to Earnings) is -8.45 and Price to Sales (PS) ratio is 13.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRTA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Prothena Corp PLC's stock?

In the past 10 years, Prothena Corp PLC has provided 0.018 (multiply by 100 for percentage) rate of return.